Antibody Mimetics/Scaffolds TRIZ Cases

See how a modified oxidase with cellulose-binding domain converts indole to indigo on textiles,

See how human embryonic stem cell-derived dendritic cells eliminate HLA-DR variability to enabl

Engineered stem cell-derived dendritic cells standardize HLA-DR antigen presentation for reliable isolation and expansion of antigen-specific CD4+ T cells.

Fusion cellulases combine catalytic and cellulose-binding domains to widen pH activity, improve washing, and limit fabric strength loss.

C-terminal CPT mutation improves folding and membrane incorporation, enabling production of higher molecular weight polyisoprenoids for rubber products.

By targeting rubber-synthesizing enzymes to lipid droplets, transgenic cells can accumulate hydrophobic compounds without waiting for slow-growing rubber trees.

Modular coiled-coil backbones and hydrogen bond networks enable selective cognate heterodimers without sacrificing protein interaction specificity.

Targeting extracellular KRT14 on cancer cells improves treatment specificity while blocking invasion and metastasis with fewer healthy-cell effects.

Engineered mice use a humanized heavy chain locus and limited universal light chains to simplify bispecific antibody pairing while maintaining fertility.

Targeted C-terminal residue changes in ISVs help predict and reduce aspecific protein interference for more reliable ADA assay results.

Bi-specific and tri-specific synthekines multimerize receptors to selectively trigger JAK/STAT, RTK, and TNFR pathways with fewer off-target effects.

Engineered yeast enzymes convert (S)-reticuline to (R)-reticuline with higher yield and lower manufacturing cost through oxidation-reduction steps.

A single fusion molecule links PTH receptor agonism with RANKL neutralization to improve bone formation, stability, and dosing convenience.

A citrullinated fibrin peptide linked to a CD38/CD138-binding antibody targets and eliminates ACPA-secreting plasma cells in rheumatoid arthritis.

A chimeric endolysin combines M23 and CHAP domains to lyse Staphylococcus cell walls and retain activity in serum against resistant biofilms.

A KRAS G12V-specific TCR binds the HLA-A1101 peptide complex, enabling transduced T cells to recognize and kill tumor cells.

Specific amino acid substitutions and directed evolution improve red fluorescent protein brightness, stability, and denaturation resistance.

A cytokine receptor endodomain paired with T-cell signaling boosts CAR T-cell survival and expansion in solid tumors without systemic cytokine toxicity.

Specific substitutions at Affibody positions 23 and 54 block eukaryotic glycosylation, preserving protein purity and antigen affinity.

Humanized CLDN18.2 antibodies use CDR grafting and sequence optimization to preserve affinity, avoid CLDN18.1 cross-reactivity, and lower immunogenicity.

Genomically edited iPSC-derived effector cells combine stable CAR integration with CD38 knockout and IL15 signaling to improve persistence and tumor killing.

Targeted DcR3 domain mutations cut mammalian-cell aggregation while preserving ligand binding and extending in vivo persistence.

Functional IDR-tagged macromolecules drive liquid-liquid demixing to co-localize reaction molecules and boost in vitro reaction efficiency without extra crowding agents.

Engineered cleavable polypeptides improve protease selectivity, in vivo stability, and localized activation of therapeutic or diagnostic payloads.

Tumor-cleavable PSMA multispecific antibodies limit systemic CD3 activation, reducing cytokine release and healthy tissue toxicity.

CRISPR-guided BASU labeling maps lncRNA-binding proteins in living cells without altering native RNA structure, improving specificity and reproducibility.

Conditionally expressed HIL-6 or L-GP130 helps CAR-T cells attack solid tumors while reducing cytokine release syndrome.

Non-integrating TERT and TERC delivery extends telomeres transiently, rejuvenating cells while avoiding genome modification and immortalization risk.

Selective humanization of rodent Tmprss genes creates an in vivo model for testing human TMPRSS-targeted antiviral compounds.

Smad signaling inhibition with an ActRII antagonist restores erythroid maturation and raises red blood cell levels when EPO is ineffective.

Conjugating GLP-2 derivatives with Fc or other carriers improves stability and prolongs blood levels, reducing frequent injections.

Engineered cysteine monoclonal antibodies enable site-specific peptide conjugation to overcome short in vivo half-life and prolong therapeutic action.

Targeted TACI domain substitutions raise APRIL and BAFF binding, improving B cell suppression for autoimmune and B cell disease therapy.

Fluorescent arrestin fusion constructs replace complex microscopy with live-cell signal readouts for reliable biased agonist screening.

Dual PD1-LAG3 binding with reduced Fc receptor interaction improves tumor-specific T cell activation while limiting side effects.

Targeted Fc mutation in canine IgG boosts FcRn binding to extend half-life, sustain serum levels, and reduce dosing frequency.

Selective VHH binding to CLL-1 creates a targeted AML therapy approach that can reach leukemia cells and cancer stem cells.

A mesothelin-gated CD40 multispecific antibody localizes APC activation in solid tumors while limiting systemic cytokine release and liver toxicity.

Single variable BCMA binders improve myeloma targeting by blocking APRIL while minimizing cross-reactivity with BAFFR and TACI.

Targeted CTLA-4 amino acid changes raise ICOSL, CD80, and CD86 binding affinity to improve immunomodulation in autoimmune and inflammatory conditions.

A receptor-binding fusion protein uses a furin-cleavable toxin linker to selectively kill HCMV-infected cells with fewer side effects.

Dual mesothelin and CD40 binding localizes APC activation in tumors, boosting anti-tumor response while limiting systemic toxicity.

Combining LAG-3 antagonists with CTLA-4 inhibition improves immune response in unresectable or metastatic melanoma after prior therapies.

Using the RSB11-R promoter to raise RSB11 expression improves rice sheath blight resistance and supports marker-assisted breeding.

A BCMA-CD3 trispecific protein uses albumin binding to extend circulation while directing T cells to selectively destroy tumor cells.

Hydrophobic interaction chromatography uses tuned buffers and UV-guided isocratic hold to remove host cell contaminants while extending resin life.

Clec4C-binding chimeric proteins target plasmacytoid dendritic cells to modulate immune responses with greater precision and fewer systemic side effects.

Co-expressing enzymes with self-crystallizing Cry proteins enables immobilization without structural modification, preserving activity and reuse.

Cell-based screening of dCas9-linked editing domain libraries identifies epigenomic editors that avoid DNA breaks and enable graded gene expression.

Controlling aflibercept truncation variants at ≤20% preserves binding and biological activity while reducing purification burden and cost.

A BCMA N-terminal Fab layout with charge and disulfide tuning improves trispecific antibody yield, affinity, and tumor killing while limiting aggregation.

A masked cytokine prodrug uses antigen and receptor co-binding to activate at disease sites, extending half-life while reducing off-target side effects.

Protein crystals are formed directly inside E. coli and analyzed by X-ray without purification, reducing crystallization effort and time.

A fused thioredoxin-thioredoxin reductase enables natural cystine-to-cysteine conversion while reducing cofactor cost and process complexity.

Cartilage-binding ISVD polypeptides inhibit ADAMTS5 and MMP13 while staying longer in joints, helping reduce frequent OA injections.

Monospecific anti-Frizzled antibodies improve tissue-targeted Wnt pathway control by binding individual receptor subtypes with high specificity.

Monomeric TSP-1 CCN fusion proteins isolate the active domain to resist proteolysis while preserving signaling and anti-fibrotic activity.

CH3 substitutions such as S354Y and Q347E bias bispecific antibodies toward heterodimers, reducing homodimers, aggregation, and yield loss.

Modified IgG Fc regions retain FcεRI binding while enabling FcRn binding, easier Protein A/G purification, and lower allergy risk.

Regulating CDPK8/CDPK9 phosphorylation of SuSy3 raises tomato sugars and soluble solids while maintaining fruit weight and flavor.

A Granzyme B+/FOXP3+ CD4+ T-cell ratio of 1 or more helps predict and monitor response to PD-1 antagonist cancer therapy.

Membrane-anchored antigen binders localize Fc-IL2 variant signaling to engineered T cells, boosting persistence while limiting systemic toxicity.

Hydrophobic self-assembly helps targeting peptides resist instability and aggregation while improving target affinity for drug delivery.

Engineered TNF-alpha variants and fusion molecules selectively bind TNFR2 to stabilize regulatory T cells and reduce inflammation.

Bypassing PD-L1 dependence, CD80 Fc fusion proteins engage CD28 and CTLA-4 to inhibit PD-L1 negative tumor growth across cancers.

Modified peptides with non-native amino acids prime B cells to produce site-specific antibodies against weak or mutation-prone protein targets.

Engineered CTLs combine a TCR and CAR to achieve epitope-specific activation and more accurate cancer cell destruction.

Specific IL-2 mutations plus Fc and anti-PD-1 fusion reduce receptor-driven toxicity, extend half-life, and sustain anti-tumor activity.

A citrate-buffered PD-L1/TGF-βRII fusion protein with sucrose, polysorbate 80, and lyophilization improves stability without losing activity.

A dual-peptide pro-moiety pairs selective PSA binding with delayed cell uptake to enable rapid activation and targeted prostate cancer delivery.

Engineered variable and Fc regions let an antigen-binding molecule target multiple immune antigens while avoiding FcγR-driven cross-linking and cytokine storms.

Specific amino acid substitutions broaden enone reductase substrate scope while preserving thermal and solvent stability for industrial biocatalysis.

Engineered Protein A binding and direct peptide insertion enable high-purity nanobody production without added linkers or folding elements.

Chromosomal intervals and markers from Glycine max SX6907 help breed soybean lines with durable resistance to diverse Asian soybean rust races.

CsgG monomers conjugated with CsgF peptides widen current range and improve SNR, enabling clearer nucleotide discrimination in nanopore sensing.

Genetic RNASET2 variants guide IBD patient stratification and targeted modulation of RNASET2 and TL1A pathways for more precise treatment.

A dBrec1-KRAB editor targets the HIV LTR to add repressive DNA and histone marks, blocking reactivation and reducing lifelong ART dependence.

Recombinant IgG-specific endoglycosidases alter Fc glycans at Asn297 to regulate inflammatory responses with fewer side effects.

By bridging DLL3-positive tumor cells and CD3 on T cells, these proteins improve cancer targeting while reducing off-target toxicity.

Multiple AML antigen targets are combined in CAR and TCR cell design to improve leukemia killing while limiting off-tumor toxicity.

Prime editing converts endogenous tRNAs into suppressor tRNAs to enable durable premature stop codon readthrough and rescue full-length protein expression.

A soluble IL-2/CD80 fusion medium expands and activates T cells without CD3/CD28 magnetic beads, reducing impurity and viral risk.

Chemically synthesized PCC agents use cooperative ligands and linkers to bind low-abundance IL-17F with high selectivity for immunoassays.

Fc-binding antibodies or fusion proteins drive ADCP-based antigen presentation to build lasting immunity while avoiding ADCC and CDC.

VLPs carrying HCMV gB and pp65 with GM-CSF target GBM-specific immune dysregulation while limiting autoimmunity risk.

Phenotypic screening on iPSC-derived brain endothelial cells identified BBB-selective antibodies that improve transcytosis and brain accumulation.

Protein contrast agents with paramagnetic metal sites and tumor-targeting peptides improve MRI specificity and sensitivity in tissues and tumors.

Selective IL-15Rβ expression restores IL-15 responsiveness in armored γδ T cells, improving persistence, proliferation, and cytotoxicity.

A mutated IdeE enzyme prevents host-cell autolysis and viscosity rise during expression, enabling stable scale-up and easier purification.

Guide RNA target recognition triggers Cas10 cyclic oligoadenylate signaling to activate nucleases for sensitive nucleic acid detection.

A single fusion protein blocks ETA signaling and traps TGF-β to reduce vascular resistance, fibrosis, and right heart strain.

Smaller VHH anti-PD-L1 antibodies improve tumor penetration while blocking PD-L1/PD-1, activating T cells, and inhibiting tumor growth.

Selective IL2Rβ/γ targeting blocks IL2Rα-driven toxicity and Treg activation while preserving stable antitumor immune stimulation.

A bispecific BCMA-CD3 binder redirects T cells to lyse multiple myeloma cells, aiming to improve efficacy while limiting side effects.

Surface-expressed CTLA-4 binding domains help therapeutic mammalian cells home to target molecules and deliver agents to specific tissues in vivo.